Latest Insider Transactions at Aquestive Therapeutics, Inc. (AQST)
This section provides a real-time view of insider transactions for Aquestive Therapeutics, Inc. (AQST). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aquestive Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aquestive Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2025
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,182
-0.73%
|
$4,364
$2.54 P/Share
|
|
Mar 10
2025
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,572
-1.31%
|
$9,144
$2.54 P/Share
|
|
Mar 09
2025
|
Daniel Barber President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
53,998
-5.05%
|
$107,996
$2.65 P/Share
|
|
Mar 09
2025
|
Peter E. Boyd See Remark |
SELL
Payment of exercise price or tax liability
|
Direct |
7,681
-2.47%
|
$15,362
$2.65 P/Share
|
|
Mar 09
2025
|
Lori J Braender Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,658
-2.58%
|
$21,316
$2.65 P/Share
|
|
Mar 09
2025
|
A Ernest Toth Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,736
-2.51%
|
$17,472
$2.65 P/Share
|
|
Mar 09
2025
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,997
-2.62%
|
$15,994
$2.65 P/Share
|
|
Mar 09
2025
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,431
-4.24%
|
$30,862
$2.65 P/Share
|
|
Mar 07
2025
|
Daniel Barber President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
29,307
-2.67%
|
$58,614
$2.65 P/Share
|
|
Mar 07
2025
|
Daniel Barber President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
272,000
+19.85%
|
-
|
|
Mar 07
2025
|
Peter E. Boyd See Remark |
SELL
Payment of exercise price or tax liability
|
Direct |
6,624
-2.09%
|
$13,248
$2.65 P/Share
|
|
Mar 07
2025
|
Peter E. Boyd See Remark |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+20.12%
|
-
|
|
Mar 07
2025
|
Lori J Braender Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,592
-2.27%
|
$19,184
$2.65 P/Share
|
|
Mar 07
2025
|
Lori J Braender Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+20.63%
|
-
|
|
Mar 07
2025
|
Sherry Korczynski SVP Sales and Marketing |
SELL
Payment of exercise price or tax liability
|
Direct |
5,428
-3.29%
|
$10,856
$2.65 P/Share
|
|
Mar 07
2025
|
Sherry Korczynski SVP Sales and Marketing |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+35.29%
|
-
|
|
Mar 07
2025
|
Carl N Kraus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,115
-2.52%
|
$16,230
$2.65 P/Share
|
|
Mar 07
2025
|
Carl N Kraus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+17.87%
|
-
|
|
Mar 07
2025
|
A Ernest Toth Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,193
-2.84%
|
$20,386
$2.65 P/Share
|
|
Mar 07
2025
|
A Ernest Toth Jr Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+23.49%
|
-
|
|
Mar 07
2025
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,361
-2.35%
|
$14,722
$2.65 P/Share
|
|
Mar 07
2025
|
Cassie Jung Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+20.35%
|
-
|
|
Mar 07
2025
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,859
-3.42%
|
$25,718
$2.65 P/Share
|
|
Mar 07
2025
|
Stephen Wargacki Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,000
+23.4%
|
-
|
|
Dec 02
2024
|
Douglas K Bratton |
SELL
Bona fide gift
|
Indirect |
40,000
-16.68%
|
-
|
|
Nov 26
2024
|
Cassie Jung Chief Operating Officer |
SELL
Open market or private sale
|
Indirect |
44
-100.0%
|
$176
$4.87 P/Share
|
|
Aug 09
2024
|
Carl N Kraus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,819
-4.12%
|
$32,457
$3.43 P/Share
|
|
Jun 07
2024
|
Sherry Korczynski SVP Sales and Marketing |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
May 10
2024
|
Stephen Wargacki Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+3.6%
|
-
|
|
Mar 15
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Open market or private sale
|
Direct |
50,000
-4.83%
|
$300,000
$6.0 P/Share
|
|
Mar 10
2024
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,132
-0.47%
|
$4,528
$4.88 P/Share
|
|
Mar 10
2024
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,687
-0.65%
|
$6,748
$4.88 P/Share
|
|
Mar 09
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,895
-0.57%
|
$23,580
$4.88 P/Share
|
|
Mar 09
2024
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,300
-3.36%
|
$33,200
$4.88 P/Share
|
|
Mar 09
2024
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,269
-4.16%
|
$45,076
$4.88 P/Share
|
|
Mar 09
2024
|
A Ernest Toth Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,705
-4.5%
|
$46,820
$4.88 P/Share
|
|
Mar 09
2024
|
Lori J Braender Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,530
-3.25%
|
$42,120
$4.88 P/Share
|
|
Mar 09
2024
|
Peter E. Boyd See Remark |
SELL
Payment of exercise price or tax liability
|
Direct |
8,370
-3.4%
|
$33,480
$4.88 P/Share
|
|
Mar 09
2024
|
Daniel Barber President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
37,938
-4.3%
|
$151,752
$4.88 P/Share
|
|
Mar 08
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.35%
|
$125,000
$5.19 P/Share
|
|
Mar 07
2024
|
Stephen Wargacki Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+29.34%
|
-
|
|
Mar 07
2024
|
Peter E. Boyd See Remark |
BUY
Grant, award, or other acquisition
|
Direct |
86,250
+25.96%
|
-
|
|
Mar 07
2024
|
Cassie Jung Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,250
+29.06%
|
-
|
|
Mar 07
2024
|
Daniel Barber President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
242,600
+21.55%
|
-
|
|
Mar 07
2024
|
Carl N Kraus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+30.0%
|
-
|
|
Mar 07
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,500
+7.19%
|
-
|
|
Mar 07
2024
|
A Ernest Toth Jr Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+31.58%
|
-
|
|
Mar 07
2024
|
Lori J Braender Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+29.43%
|
-
|
|
Aug 09
2023
|
Carl N Kraus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+50.0%
|
-
|
|
Mar 10
2023
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,981
-1.24%
|
$0
$0.79 P/Share
|